Egypt, Israel, Lebanon & Saudi Arabia: Clinical Development Profile

Report Overview

Finding patients to participate in clinical trials is a constant struggle in the pharmaceutical industry.  The challenging nature of recruitment leads both sponsors and service providers to consistently explore new geographies to find appropriate patient populations. The largest CROs have made several recent acquisitions and agreements in the Middle East and North Africa region which may indicate that clinical trial activity in the area is poised to increase.

In this report, ISR provides insight into the clinical trial regulation and development environment, sponsor and service provider activities, and population “health status” for Egypt, Israel, Lebanon, and Saudi Arabia. Consider this report a “primer” for learning about clinical trials in the region.

What you will learn:

• How population health status, regulations, clinical trial activity, and international and domestic company partnerships make Egypt, Israel, Lebanon, and Saudi Arabia some of the top emerging global pharmaceutical markets
• Insights from domestic service provider organizations on conducting clinical trials in Egypt, Israel, Lebanon and Saudi Arabia
• Clinical trial operational metrics for country-specific clinical studies
• Compiled lists and contact details for domestic and international service providers

How you can use this report:

• Understand how Egypt, Israel, Lebanon, and Saudi Arabi compare to other countries on a variety of health condition scales so the reader can consider the areas in which they may be beneficial as trial sites
• Understand the legal, logistical, and regulatory details for conducting clinicals trials, and illustrate the benefits and drawbacks of conducting trials in Egypt, Israel, Lebanon, and Saudi Arabia

Methodology:

ISR gathered content for this report via an exhaustive secondary research effort and from company profile questionnaires that were distributed to CROs profiled in this report.